Mechanisms of diabetic microvascular complications

Joslin's Diabetes Mellitus: Fourteenth Edition

Volumn , Issue , 2011, Pages 823-837

  Rask Madsen, Christian ^a   He, Zhiheng ^a   King, George L ^a,b  

^a JOSLIN DIABETES CENTER   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84970954345     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (313)

1. Chou E, Suzuma I, Way KJ, et al. Decreased cardiac expression of vascular endothelial growth factor and its receptors in insulin-resistant and diabetic states: a possible explanation for impaired collateral formation in cardiac tissue. Circulation 2002;105:373-379.
2. Sharma K, Jin Y, Guo J, et al. Neutralization of TGF-beta by anti-TGF-beta antibody attenuates kidney hypertrophy and the enhanced extracellular matrix gene expression in STZ-induced diabetic mice. Diabetes 1996;45: 522-530.
3. Ziyadeh FN, Hoffman BB, Han DC, et al. Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-beta antibody in db/db diabetic mice. Proc Natl Acad Sci U S A 2000;97: 8015-8020.
4. van Royen N, Hoefer I, Buschmann I, et al. Exogenous application of transforming growth factor beta 1 stimulates arteriogenesis in the peripheral circulation. FASEB J 2002;16:432-434.
5. Murata M, Ohta N, Fujisawa S, et al. Selective pericyte degeneration in the retinal capillaries of galactose-fed dogs results from apoptosis linked to aldose reductase-catalyzed galactitol accumulation. . Diabetes Complications 2002;16:363-370.
6. Romeo G, Liu WH, Asnaghi V, et al. Activation of nuclear factor-kappaB induced by diabetes and high glucose regulates a proapoptotic program in retinal pericytes. Diabetes 2002;51:2241-3348.
7. Pomero F, Allione A, Beltramo E, et al. Effects of protein kinase C inhibition and activation on proliferation and apoptosis of bovine retinal pericytes. Diabetologia 2003;46:416-419.
8. Yamagishi S, Amano S, Inagaki Y, et al. Advanced glycation end productsinduced apoptosis and overexpression of vascular endothelial growth factor in bovine retinal pericytes. Biochem Biophys Res Commun 2002;290:973-978.
9. Frustaci A, Kajstura J, Chimenti C, et al. Myocardial cell death in human diabetes. Circ Res 2000;87:1123-1132.
10. Ho FM, Liu SH, Liau CS, et al. High glucose-induced apoptosis in human endothelial cells is mediated by sequential activations of c-Jun NH(2)-terminal kinase and caspase-3. Circulation 2000;101:2618-2624.
11. Bergstrand A, Bucht H. The glomerular lesions of diabetes mellitus and their electron-microscope appearances. . Pathol Bacteriol 1959;77:231-242.
12. Shimomura H, Spiro RG. Studies on macromolecular components of human glomerular basement membrane and alterations in diabetes. Decreased levels of heparan sulfate proteoglycan and laminin. Diabetes 1987;36:374-381.
13. Beisswenger PJ, Spiro RG. Studies on the human glomerular basement membrane. Composition, nature of the carbohydrate units and chemical changes in diabetes mellitus. Diabetes 1973;22:180-193.
14. Mason RM, Wahab NA. Extracellular matrix metabolism in diabetic nephropathy. . Am Soc Nephrol 2003;14:1358-1373.
15. Nagata M, Katz ML, Robison WG Jr. Age-related thickening of retinal capillary basement membranes. Invest Ophthalmol Vis Sci 1986;27:437-440.
16. Robison WG Jr, Kador PF, Kinoshita JH. Retinal capillaries: basement membrane thickening by galactosemia prevented with aldose reductase inhibitor. Science 1983;221:1177-1179.
17. Fischer F, Gartner J. Morphometric analysis of basal laminae in rats with longterm streptozotocin diabetes L. II. Retinal capillaries. Exp Eye Res 1983; 37:55-64.
18. van den Born J, van Kraats AA, Bakker MA, et al. Reduction of heparan sulphate-associated anionic sites in the glomerular basement membrane of rats with streptozotocin-induced diabetic nephropathy. Diabetologia 1995;38: 1169-1175.
19. van den Born J, van Kraats AA, Bakker MA, et al. Selective proteinuria in diabetic nephropathy in the rat is associated with a relative decrease in glomerular basement membrane heparan sulphate. Diabetologia 1995;38: 161-172.
20. Singh R, Alavi N, Singh AK, et al. Role of angiotensin II in glucose-induced inhibition of mesangial matrix degradation. Diabetes 1999;48:2066-2073.
21. Abdel Wahab N, Mason RM. Modulation of neutral protease expression in human mesangial cells by hyperglycaemic culture. Biochem J 1996;320: 777-783.
22. Shankland SJ, Ly H, Thai K, et al. Glomerular expression of tissue inhibitor of metalloproteinase (TIMP-1) in normal and diabetic rats. . Am Soc Nephrol 1996;7:97-104.
23. Tesfamariam B, Cohen RA. Free radicals mediate endothelial cell dysfunction caused by elevated glucose. Am J Physiol 1992;263:H321-H326.
24. Williams SB, Goldfine AB, Timimi FK, et al. Acute hyperglycemia attenuates endothelium-dependent vasodilation in humans in vivo. Circulation 1998;97: 1695-1701.
25. Nilsson SF. The significance of nitric oxide for parasympathetic vasodilation in the eye and other orbital tissues in the cat. Exp Eye Res 2000;70:61-72.
26. Dorner GT, Garhofer G, Kiss B, et al. Nitric oxide regulates retinal vascular tone in humans. Am J Physiol Heart Circ Physiol 2003;285:H631-H636.
27. Ishii H, Jirousek MR, Koya D, et al. Amelioration of vascular dysfunctions in diabetic rats by an oral PKC beta inhibitor. Science 1996;272:728-731.
28. Kihara M, Low PA. Impaired vasoreactivity to nitric oxide in experimental diabetic neuropathy. Exp Neurol 1995;132:180-185.
29. El-Remessy AB, Behzadian MA, Abou-Mohamed G, et al. Experimental diabetes causes breakdown of the blood-retina barrier by a mechanism involving tyrosine nitration and increases in expression of vascular endothelial growth factor and urokinase plasminogen activator receptor. Am J Pathol 2003;162:1995-2004.
30. Takeda M, Mori F, Yoshida A, et al. Constitutive nitric oxide synthase is associated with retinal vascular permeability in early diabetic rats. Diabetologia 2001;44:1043-1050.
31. Joussen AM, Poulaki V, Mitsiades N, et al. Nonsteroidal anti-inflammatory drugs prevent early diabetic retinopathy via TNF-alpha suppression. FASEB J 2002;16:438-440.
32. Joussen AM, Poulaki V, Qin W, et al. Retinal vascular endothelial growth factor induces intercellular adhesion molecule-1 and endothelial nitric oxide synthase expression and initiates early diabetic retinal leukocyte adhesion in vivo. Am J Pathol 2002;160:501-509.
33. Kowluru RA. Effect of reinstitution of good glycemic control on retinal oxidative stress and nitrative stress in diabetic rats. Diabetes 2003;52: 818-823.
34. Thylefors B, Negrel AD, Pararajasegaram R, et al. Global data on blindness. Bull World Health Organ 1995;73:115-121.
35. Cai J, Boulton M. The pathogenesis of diabetic retinopathy: old concepts and new questions. Eye 2002;16:242-260.
36. Ferris FL 3rd, Davis MD, Aiello LM. Treatment of diabetic retinopathy. . Engl J Med 1999;341:667-678.
37. Allt G, Lawrenson JG. Pericytes: cell biology and pathology. Cells Tissues Organs 2001;169:1-11.
38. Hirschi KK, D'Amore PA. Pericytes in the microvasculature. Cardiovasc Res 1996;32:687-698.
39. Midena E, Segato T, Radin S, et al. Studies on the retina of the diabetic db/db mouse. I. Endothelial cell-pericyte ratio. Ophthalmic Res 1989;21:106-111.
40. Agardh CD, Agardh E, Zhang H, et al. Altered endothelial/pericyte ratio in Goto-Kakizaki rat retina. . Diabetes Complications 1997;11:158-162.
41. Morisaki N, Watanabe S, Fukuda K, et al. Angiogenic interaction between retinal endothelial cells and pericytes from normal and diabetic rabbits, and phenotypic changes of diabetic cells. Cell Mol Biol (Noisy-le-grand) 1999;45: 67-77.
42. Benjamin LE, Hemo I, Keshet E. Aplasticity window for blood vessel remodelling is defined by pericyte coverage of the preformed endothelial network and is regulated by PDGF-B and VEGF. Development 1998;125: 1591-1598.
43. Benjamin LE, Golijanin D, Itin A, et al. Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. . Clin Invest 1999;103:159-165.
44. Lindahl P, Johansson BR, Leveen P, et al. Pericyte loss and microaneurysm formation in PDGF-B-deficient mice. Science 1997;277:242-245.
45. Osterby R, Gundersen HJ. Glomerular size and structure in diabetes mellitus. I. Early abnormalities. Diabetologia 1975;11:225-229.
46. Osterby R, Gundersen HJ. Fast accumulation of basement membrane material and the rate of morphological changes in acute experimental diabetic glomerular hypertrophy. Diabetologia 1980;18:493-500.
47. Kimmelstiel P, Wilson C. Intercapillary lesions in the glomeruli of the kidney. Am J Pathol 1936;12:83-98.
48. Wiseman MJ, Saunders AJ, Keen H, et al. Effect of blood glucose control on increased glomerular filtration rate and kidney size in insulin-dependent diabetes. . Engl J Med 1985;312:617-621.
49. Steffes MW, Brown DM, Basgen JM, et al. Amelioration of mesangial volume and surface alterations following islet transplantation in diabetic rats. Diabetes 1980;29:509-515.
50. Nakamura Y, Myers BD. Charge selectivity of proteinuria in diabetic glomerulopathy. Diabetes 1988;37:1202-1211.
51. Cooper ME. Interaction of metabolic and haemodynamic factors in mediating experimental diabetic nephropathy. Diabetologia 2001;44:1957-1972.
52. Dyck PJ, Kratz KM, Karnes JL, et al. The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population-based cohort: the Rochester Diabetic Neuropathy Study. Neurology 1993;43:817-824.
53. Eichberg J. Protein kinase C changes in diabetes: is the concept relevant to neuropathy? Int Rev Neurobiol 2002;50:61-82.
54. Sugimoto K, Murakawa Y, Sima AA. Diabetic neuropathy-a continuing enigma. Diabetes Metab Res Rev 2000;16:408-433.
55. Malik RA, Tesfaye S, Thompson SD, et al. Endoneurial localisation of microvascular damage in human diabetic neuropathy. Diabetologia 1993;36: 454-459.
56. Schratzberger P, Walter DH, Rittig K, et al. Reversal of experimental diabetic neuropathy by VEGF gene transfer. . Clin Invest 2001;107:1083-1092.
57. Nakamura J, Kato K, Hamada Y, et al. A protein kinase C-beta-selective inhibitor ameliorates neural dysfunction in streptozotocin-induced diabetic rats. Diabetes 1999;48:2090-2095.
58. Cameron NE, Cotter MA. Effects of protein kinase Cbeta inhibition on neurovascular dysfunction in diabetic rats: interaction with oxidative stress and essential fatty acid dysmetabolism. Diabetes Metab Res Rev 2002;18: 315-323.
59. Kannel WB, Hjortland M, Castelli WP. Role of diabetes in congestive heart failure: the Framingham study. Am J Cardiol 1974;34:29-34.
60. Stone PH, Muller JE, Hartwell T, et al. The MILIS Study Group. The effect of diabetes mellitus on prognosis and serial left ventricular function after acute myocardial infarction: contribution of both coronary disease and diastolic left ventricular dysfunction to the adverse prognosis. . Am Coll Cardiol 1989; 14:49-57.
61. Poirier P, Bogaty P, Garneau C, et al. Diastolic dysfunction in normotensive men with well-controlled type 2 diabetes: importance of maneuvers in echocardiographic screening for preclinical diabetic cardiomyopathy. Diabetes Care 2001;24:5-10.
62. Abaci A, Oguzhan A, Kahraman S, et al. Effect of diabetes mellitus on formation of coronary collateral vessels. Circulation 1999;99:2239-2242.
63. Yarom R, Zirkin H, Stammler G, et al. Human coronary microvessels in diabetes and ischaemia. Morphometric study of autopsy material. . Pathol 1992; 166:265-270.
64. Thompson EW. Quantitative analysis of myocardial structure in insulindependent diabetes mellitus: effects of immediate and delayed insulin replacement. Proc Soc Exp Biol Med 1994;205:294-305.
65. Warley A, Powell JM, Skepper JN. Capillary surface area is reduced and tissue thickness from capillaries to myocytes is increased in the left ventricle of streptozotocin-diabetic rats. Diabetologia 1995;38:413-421.
66. Yamaji T, Fukuhara T, Kinoshita M. Increased capillary permeability to albumin in diabetic rat myocardium. Circ Res 1993;72:947-957.
67. Freedman SB, Isner JM. Therapeutic angiogenesis for coronary artery disease. Ann Intern Med 2002;136:54-71.
68. Regan TJ, Lyons MM, Ahmed SS, et al. Evidence for cardiomyopathy in familial diabetes mellitus. . Clin Invest 1977;60:884-899.
69. Spiro MJ, Crowley TJ. Increased rat myocardial type VI collagen in diabetes mellitus and hypertension. Diabetologia 1993;36:93-98.
70. Chen S, Evans T, Mukherjee K, et al. Diabetes-induced myocardial structural changes: role of endothelin-1 and its receptors. . Mol Cell Cardiol 2000;32: 1621-1629.
71. Hoyer J, Kohler R, Haase W, et al. Up-regulation of pressure-activated Ca(2+)-permeable cation channel in intact vascular endothelium of hypertensive rats. Proc Natl Acad Sci U S A 1996;93:11253-11258.
72. Hamada K, Takuwa N, Yokoyama K, et al. Stretch activates Jun N-terminal kinase/stress-activated protein kinase in vascular smooth muscle cells through mechanisms involving autocrine ATP stimulation of purinoceptors. . Biol Chem 1998;273:6334-6340.
73. Chen KD, Li YS, Kim M, et al. Mechanotransduction in response to shear stress. Roles of receptor tyrosine kinases, integrins, and Shc. . Biol Chem 1999; 274:18393-18400.
74. Kelly DJ, Skinner SL, Gilbert RE, et al. Effects of endothelin or angiotensin II receptor blockade on diabetes in the transgenic (mRen-2)27 rat. Kidney Int 2000;57:1882-1894.
75. Perin PC, Maule S, Quadri R. Sympathetic nervous system, diabetes, and hypertension. Clin Exp Hypertens 2001;23:45-55.
76. Scherrer U, Sartori C. Insulin as a vascular and sympathoexcitatory hormone: implications for blood pressure regulation, insulin sensitivity, and cardiovascular morbidity. Circulation 1997;96:4104-4113.
77. Brownlee M. Advanced protein glycosylation in diabetes and aging. Annu Rev Med 1995;46:223-234.
78. Giardino I, Edelstein D, Brownlee M. BCL-2 expression or antioxidants prevent hyperglycemia-induced formation of intracellular advanced glycation endproducts in bovine endothelial cells. . Clin Invest 1996;97:1422-1428.
79. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001;414:813-820.
80. Schleicher ED, Wagner E, Nerlich AG. Increased accumulation of the glycoxidation product N(epsilon)-(carboxymethyl)lysine in human tissues in diabetes and aging. . Clin Invest 1997;99:457-468.
81. Schmidt AM, Yan SD, Wautier JL, et al. Activation of receptor for advanced glycation end products: a mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis. Circ Res 1999;84:489-497.
82. Stitt AW, Li YM, Gardiner TA, et al. Advanced glycation end products (AGEs) co-localize with AGE receptors in the retinal vasculature of diabetic and of AGE-infused rats. Am J Pathol 1997;150:523-531.
83. Horie K, Miyata T, Maeda K, et al. Immunohistochemical colocalization of glycoxidation products and lipid peroxidation products in diabetic renal glomerular lesions. Implication for glycoxidative stress in the pathogenesis of diabetic nephropathy. . Clin Invest 1997;100:2995-3004.
84. Bucala R, Tracey KJ, Cerami A. Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilatation in experimental diabetes. . Clin Invest 1991;87:432-438.
85. Giardino I, Edelstein D, Brownlee M. Nonenzymatic glycosylation in vitro and in bovine endothelial cells alters basic fibroblast growth factor activity. A model for intracellular glycosylation in diabetes. . Clin Invest 1994;94: 110-117.
86. Mott JD, Khalifah RG, Nagase H, et al. Nonenzymatic glycation of type IV collagen and matrix metalloproteinase susceptibility. Kidney Int 1997;52: 1302-1312.
87. Tanaka S, Avigad G, Brodsky B, et al. Glycation induces expansion of the molecular packing of collagen. . Mol Biol 1988;203:495-505.
88. Tsilibary EC, Charonis AS, Reger LA, et al. The effect of nonenzymatic glucosylation on the binding of the main noncollagenous NC1 domain to type IV collagen. . Biol Chem 1988;263:4302-4308.
89. Charonis AS, Reger LA, Dege JE, et al. Laminin alterations after in vitro nonenzymatic glycosylation. Diabetes 1990;39:807-814.
90. Haitoglou CS, Tsilibary EC, Brownlee M, et al. Altered cellular interactions between endothelial cells and nonenzymatically glucosylated laminin/type IV collagen. . Biol Chem 1992;267:12404-12407.
91. Oldfield MD, Bach LA, Forbes JM, et al. Advanced glycation end products cause epithelial-myofibroblast transdifferentiation via the receptor for advanced glycation end products (RAGE). . Clin Invest 2001;108:1853-1863.
92. Yamamoto Y, Kato I, Doi T, et al. Development and prevention of advanced diabetic nephropathy in RAGE-overexpressing mice. . Clin Invest 2001;108: 261-268.
93. Rojas A, Romay S, Gonzalez D, et al. Regulation of endothelial nitric oxide synthase expression by albumin-derived advanced glycosylation end products. Circ Res 2000;86:E50-E54.
94. Quehenberger P, Bierhaus A, Fasching P, et al. Endothelin 1 transcription is controlled by nuclear factor-kappaB in AGE-stimulated cultured endothelial cells. Diabetes 2000;49:1561-1570.
95. Bierhaus A, Chevion S, Chevion M, et al. Advanced glycation end productinduced activation of NF-kappaB is suppressed by alpha-lipoic acid in cultured endothelial cells. Diabetes 1997;46:1481-1490.
96. Rumble JR, Cooper ME, Soulis T, et al. Vascular hypertrophy in experimental diabetes. Role of advanced glycation end products. . Clin Invest 1997;99: 1016-1027.
97. Lu M, Kuroki M, Amano S, et al. Advanced glycation end products increase retinal vascular endothelial growth factor expression. . Clin Invest 1998;101: 1219-1224.
98. Yamagishi S, Fujimori H, Yonekura H, et al. Advanced glycation endproducts inhibit prostacyclin production and induce plasminogen activator inhibitor-1 in human microvascular endothelial cells. Diabetologia 1998;41: 1435-1441.
99. Basta G, Lazzerini G, Massaro M, et al. Advanced glycation end products activate endothelium through signal-transduction receptor RAGE: a mechanism for amplification of inflammatory responses. Circulation 2002;105: 816-822.
100. Wautier JL, Zoukourian C, Chappey O, et al. Receptor-mediated endothelial cell dysfunction in diabetic vasculopathy. Soluble receptor for advanced glycation end products blocks hyperpermeability in diabetic rats. . Clin Invest 1996;97:238-243.
101. Soulis-Liparota T, Cooper M, Papazoglou D, et al. Retardation by aminoguanidine of development of albuminuria, mesangial expansion, and tissue fluorescence in streptozocin-induced diabetic rat. Diabetes 1991;40: 1328-1334.
102. Hammes HP, Martin S, Federlin K, et al. Aminoguanidine treatment inhibits the development of experimental diabetic retinopathy. Proc Natl Acad Sci U S A 1991;88:11555-11558.
103. Soulis T, Sastra S, Thallas V, et al. A novel inhibitor of advanced glycation end-product formation inhibits mesenteric vascular hypertrophy in experimental diabetes. Diabetologia 1999;42:472-479.
104. Kass DA, Shapiro EP, Kawaguchi M, et al. Improved arterial compliance by a novel advanced glycation end-product crosslink breaker. Circulation 2001; 104:1464-1470.
105. Nakamura S, Makita Z, Ishikawa S, et al. Progression of nephropathy in spontaneous diabetic rats is prevented by OPB-9195, a novel inhibitor of advanced glycation. Diabetes 1997;46:895-899.
106. Forbes JM, Cooper ME, Thallas V, et al. Reduction of the accumulation of advanced glycation end products by ACE inhibition in experimental diabetic nephropathy. Diabetes 2002;51:3274-3282.
107. Adamis AP. Is diabetic retinopathy an inflammatory disease? Br J Ophthalmol 2002;86:363-365.
108. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. . Engl J Med 1993;329:977-986.
109. Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995;28:103-117.
110. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-853.
111. Yki-Jarvinen H, Makimattila S. Insulin resistance due to hyperglycaemia: an adaptation protecting insulin-sensitive tissues. Diabetologia 1997;40[Suppl 2]:S141-S144.
112. Kaiser N, Sasson S, Feener EP, et al. Differential regulation of glucose transport and transporters by glucose in vascular endothelial and smooth muscle cells. Diabetes 1993;42:80-89.
113. Heilig CW, Concepcion LA, Riser BL, et al. Overexpression of glucose transporters in rat mesangial cells cultured in a normal glucose milieu mimics the diabetic phenotype. . Clin Invest 1995;96:1802-1814.
114. Badr GA, Tang J, Ismail-Beigi F, et al. Diabetes downregulates GLUT1 expression in the retina and its microvessels but not in the cerebral cortex or its microvessels. Diabetes 2000;49:1016-1021.
115. King GL, Buzney SM, Kahn CR, et al. Differential responsiveness to insulin of endothelial and support cells from micro-and macrovessels. . Clin Invest 1983;71:974-979.
116. Baynes JW. Role of oxidative stress in development of complications in diabetes. Diabetes 1991;40:405-412.
117. Giugliano D, Ceriello A, Paolisso G. Oxidative stress and diabetic vascular complications. Diabetes Care 1996;19:257-267.
118. Keaney JF Jr, Larson MG, Vasan RS, et al. Obesity and systemic oxidative stress: clinical correlates of oxidative stress in the Framingham Study. Arterioscler Thromb Vasc Biol 2003;23:434-439.
119. Jain SK, McVie R. Effect of glycemic control, race (white versus black), and duration of diabetes on reduced glutathione content in erythrocytes of diabetic patients. Metabolism 1994;43:306-309.
120. Kimura F, Hasegawa G, Obayashi H, et al. Serum extracellular superoxide dismutase in patients with type 2 diabetes: relationship to the development of micro-and macrovascular complications. Diabetes Care 2003;26:1246-1250.
121. Augustin AJ, Dick HB, Koch F, et al. Correlation of blood-glucose control with oxidative metabolites in plasma and vitreous body of diabetic patients. Eur J Ophthalmol 2002;12:94-101.
122. Craven PA, Melhem MF, Phillips SL, et al. Overexpression of Cu2+/Zn2+ superoxide dismutase protects against early diabetic glomerular injury in transgenic mice. Diabetes 2001;50:2114-2125.
123. Kowluru RA, Tang J, Kern TS. Abnormalities of retinal metabolism in diabetes and experimental galactosemia. VII. Effect of long-term administration of antioxidants on the development of retinopathy. Diabetes 2001;50:1938-1942.
124. Lal MA, Korner A, Matsuo Y, et al. Combined antioxidant and COMT inhibitor treatment reverses renal abnormalities in diabetic rats. Diabetes 2000;49:1381-1389.
125. Cameron NE, Cotter MA, Archibald V, et al. Anti-oxidant and pro-oxidant effects on nerve conduction velocity, endoneurial blood flow and oxygen tension in non-diabetic and streptozotocin-diabetic rats. Diabetologia 1994;37: 449-459.
126. Nagamatsu M, Nickander KK, Schmelzer JD, et al. Lipoic acid improves nerve blood flow, reduces oxidative stress, and improves distal nerve conduction in experimental diabetic neuropathy. Diabetes Care 1995;18:1160-1167.
127. Gaede P, Poulsen HE, Parving HH, et al. Double-blind, randomised study of the effect of combined treatment with vitamin C and E on albuminuria in type 2 diabetic patients. Diabet Med 2001;18:756-760.
128. Bursell SE, Clermont AC, Aiello LP, et al. High-dose vitamin E supplementation normalizes retinal blood flow and creatinine clearance in patients with type 1 diabetes. Diabetes Care 1999;22:1245-1251.
129. Tutuncu NB, Bayraktar M, Varli K. Reversal of defective nerve conduction with vitamin E supplementation in type 2 diabetes: a preliminary study. Diabetes Care 1998;21:1915-1918.
130. Lonn E, Yusuf S, Hoogwerf B, et al. Effects of vitamin E on cardiovascular and microvascular outcomes in high-risk patients with diabetes: results of the HOPE study and MICRO-HOPE substudy. Diabetes Care 2002;25:1919-1927.
131. Garcia Soriano F, Virag L, Jagtap P, et al. Diabetic endothelial dysfunction: the role of poly(ADP-ribose) polymerase activation. Nat Med 2001;7:108-113.
132. Du X, Matsumura T, Edelstein D, et al. Inhibition of GAPDH activity by poly(ADP-ribose) polymerase activates three major pathways of hyperglycemic damage in endothelial cells. . Clin Invest 2003;112:1049-1057.
133. Williamson JR, Chang K, Frangos M, et al. Hyperglycemic pseudohypoxia and diabetic complications. Diabetes 1993;42:801-813.
134. Engerman RL, Kern TS, Larson ME. Nerve conduction and aldose reductase inhibition during 5 years of diabetes or galactosaemia in dogs. Diabetologia 1994;37:141-144.
135. Greene DA, Arezzo JC, Brown MB. Zenarestat Study Group. Effect of aldose reductase inhibition on nerve conduction and morphometry in diabetic neuropathy. Neurology 1999;53:580-591.
136. Sorbinil Retinopathy Trial Research Group. Arandomized trial of sorbinil, an aldose reductase inhibitor, in diabetic retinopathy. Arch Ophthalmol 1990;108: 1234-1244.
137. Asahina T, Kashiwagi A, Nishio Y, et al. Impaired activation of glucose oxidation and NADPH supply in human endothelial cells exposed to H2O2 in high-glucose medium. Diabetes 1995;44:520-526.
138. Zhang Z, Apse K, Pang J, et al. High glucose inhibits glucose-6-phosphate dehydrogenase via cAMP in aortic endothelial cells. . Biol Chem 2000;275: 40042-40047.
139. Leopold JA, Cap A, Scribner AW, et al. Glucose-6-phosphate dehydrogenase deficiency promotes endothelial oxidant stress and decreases endothelial nitric oxide bioavailability. FASEB J 2001;15:1771-1773.
140. Nishikawa T, Edelstein D, Du XL, et al. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 2000;404:787-790.
141. Griendling KK, Sorescu D, Ushio-Fukai M. NAD(P)H oxidase: role in cardiovascular biology and disease. Circ Res 2000;86:494-501.
142. Gorlach A, Brandes RP, Nguyen K, et al. Agp91phox containing NADPH oxidase selectively expressed in endothelial cells is a major source of oxygen radical generation in the arterial wall. Circ Res 2000;87:26-32.
143. Hink U, Li H, Mollnau H, et al. Mechanisms underlying endothelial dysfunction in diabetes mellitus. Circ Res 2001;88:E14-E22.
144. Kim YK, Lee MS, Son SM, et al. Vascular NADH oxidase is involved in impaired endothelium-dependent vasodilation in OLETF rats, a model of type 2 diabetes. Diabetes 2002;51:522-527.
145. Mohazzab KM, Kaminski PM, Wolin MS. NADH oxidoreductase is a major source of superoxide anion in bovine coronary artery endothelium. Am J Physiol 1994;266:H2568-H2572.
146. Inoguchi T, Li P, Umeda F, et al. High glucose level and free fatty acid stimulate reactive oxygen species production through protein kinase C-dependent activation of NAD(P)H oxidase in cultured vascular cells. Diabetes 2000;49: 1939-1945.
147. Duerrschmidt N, Wippich N, Goettsch W, et al. Endothelin-1 induces NAD(P)H oxidase in human endothelial cells. Biochem Biophys Res Commun 2000;269:713-717.
148. Ohara Y, Peterson TE, Harrison DG. Hypercholesterolemia increases endothelial superoxide anion production. . Clin Invest 1993;91:2546-2551.
149. Laursen JB, Somers M, Kurz S, et al. Endothelial regulation of vasomotion in apoE-deficient mice: implications for interactions between peroxynitrite and tetrahydrobiopterin. Circulation 2001;103:1282-1288.
150. Mayer B, John M, Bohme E. Purification of a Ca2+/calmodulin-dependent nitric oxide synthase from porcine cerebellum. Cofactor-role of tetrahydrobiopterin. FEBS Lett 1990;277:215-219.
151. Wever R, Luscher TF, Cosentino F, et al. Atherosclerosis and the two faces of endothelial nitric oxide synthase. Circulation 1998;97:108-112.
152. Zou MH, Shi C, Cohen RA. Oxidation of the zinc-thiolate complex and uncoupling of endothelial nitric oxide synthase by peroxynitrite. . Clin Invest 2002;109:817-826.
153. Shinozaki K, Kashiwagi A, Nishio Y, et al. Abnormal biopterin metabolism is a major cause of impaired endothelium-dependent relaxation through nitric oxide/O2-imbalance in insulin-resistant rat aorta. Diabetes 1999;48:2437-2445.
154. Shinozaki K, Nishio Y, Okamura T, et al. Oral administration of tetrahydrobiopterin prevents endothelial dysfunction and vascular oxidative stress in the aortas of insulin-resistant rats. Circ Res 2000;87:566-573.
155. Heitzer T, Krohn K, Albers S, et al. Tetrahydrobiopterin improves endothelium-dependent vasodilation by increasing nitric oxide activity in patients with type II diabetes mellitus. Diabetologia 2000;43:1435-1438.
156. MacMillan-Crow LA, Crow JP, Kerby JD, et al. Nitration and inactivation of manganese superoxide dismutase in chronic rejection of human renal allografts. Proc Natl Acad Sci U S A 1996;93:11853-11858.
157. Turko IV, Marcondes S, Murad F. Diabetes-associated nitration of tyrosine and inactivation of succinyl-CoA:3-oxoacid CoA-transferase. Am J Physiol Heart Circ Physiol 2001;281:H2289-H2294.
158. Zou MH, Shi C, Cohen RA. High glucose via peroxynitrite causes tyrosine nitration and inactivation of prostacyclin synthase that is associated with thromboxane/prostaglandin H(2) receptor-mediated apoptosis and adhesion molecule expression in cultured human aortic endothelial cells. Diabetes 2002;51:198-203.
159. Desco MC, Asensi M, Marquez R, et al. Xanthine oxidase is involved in free radical production in type 1 diabetes: protection by allopurinol. Diabetes 2002;51:1118-1124.
160. Hunt JV, Dean RT, Wolff SP. Hydroxyl radical production and autoxidative glycosylation. Glucose autoxidation as the cause of protein damage in the experimental glycation model of diabetes mellitus and ageing. Biochem J 1988;256:205-212.
161. Jain SK, McVie R, Jackson R, et al. Effect of hyperketonemia on plasma lipid peroxidation levels in diabetic patients. Diabetes Care 1999;22:1171-1175.
162. Ceriello A, dello Russo P, Amstad P, et al. High glucose induces antioxidant enzymes in human endothelial cells in culture. Evidence linking hyperglycemia and oxidative stress. Diabetes 1996;45:471-477.
163. Urata Y, Yamamoto H, Goto S, et al. Long exposure to high glucose concentration impairs the responsive expression of gamma-glutamylcysteine synthetase by interleukin-1beta and tumor necrosis factor-alpha in mouse endothelial cells. . Biol Chem 1996;271:15146-15152.
164. Wells L, Vosseller K, Hart GW. Glycosylation of nucleocytoplasmic proteins: signal transduction and O-GlcNAc. Science 2001;291:2376-2378.
165. Schleicher ED, Weigert C. Role of the hexosamine biosynthetic pathway in diabetic nephropathy. Kidney Int Suppl 2000;77:S13-S18.
166. Nerlich AG, Sauer U, Kolm-Litty V, et al. Expression of glutamine:fructose-6-phosphate amidotransferase in human tissues: evidence for high variability and distinct regulation in diabetes. Diabetes 1998;47:170-178.
167. James LR, Ingram A, Ly H, et al. Angiotensin II activates the GFAT promoter in mesangial cells. Am J Physiol Renal Physiol 2001;281:F151-F162.
168. Du XL, Edelstein D, Dimmeler S, et al. Hyperglycemia inhibits endothelial nitric oxide synthase activity by posttranslational modification at the Akt site. . Clin Invest 2001;108:1341-1348.
169. Federici M, Menghini R, Mauriello A, et al. Insulin-dependent activation of endothelial nitric oxide synthase is impaired by O-linked glycosylation modification of signaling proteins in human coronary endothelial cells. Circulation 2002;106:466-472.
170. James LR, Tang D, Ingram A, et al. Flux through the hexosamine pathway is a determinant of nuclear factor kappaB-dependent promoter activation. Diabetes 2002;51:1146-1156.
171. James LR, Fantus IG, Goldberg H, et al. Overexpression of GFAT activates PAI-1 promoter in mesangial cells. Am J Physiol Renal Physiol 2000;279:F718-F727.
172. Du XL, Edelstein D, Rossetti L, et al. Hyperglycemia-induced mitochondrial superoxide overproduction activates the hexosamine pathway and induces plasminogen activator inhibitor-1 expression by increasing Sp1 glycosylation. Proc Natl Acad Sci U S A 2000;97:12222-12226.
173. Goldberg HJ, Whiteside CI, Fantus IG. The hexosamine pathway regulates the plasminogen activator inhibitor-1 gene promoter and Sp1 transcriptional activation through protein kinase C-beta I and -delta. . Biol Chem 2002;277: 33833-33841.
174. McClain DA, Paterson AJ, Roos MD, et al. Glucose and glucosamine regulate growth factor gene expression in vascular smooth muscle cells. Proc Natl Acad Sci U S A 1992;89:8150-8154.
175. Lee TS, Saltsman KA, Ohashi H, et al. Activation of protein kinase C by elevation of glucose concentration: proposal for a mechanism in the development of diabetic vascular complications. Proc Natl Acad Sci U S A 1989;86: 5141-5145.
176. Inoguchi T, Xia P, Kunisaki M, et al. Insulin's effect on protein kinase C and diacylglycerol induced by diabetes and glucose in vascular tissues. Am J Physiol 1994;267:E369-E379.
177. Yu HY, Inoguchi T, Kakimoto M, et al. Saturated non-esterified fatty acids stimulate de novo diacylglycerol synthesis and protein kinase C activity in cultured aortic smooth muscle cells. Diabetologia 2001;44:614-620.
178. Koya D, Haneda M, Nakagawa H, et al. Amelioration of accelerated diabetic mesangial expansion by treatment with a PKC beta inhibitor in diabetic db/db mice, a rodent model for type 2 diabetes. FASEB J 2000;14: 439-447.
179. Shinomura T, Asaoka Y, Oka M, et al. Synergistic action of diacylglycerol and unsaturated fatty acid for protein kinase C activation: its possible implications. Proc Natl Acad Sci U S A 1991;88:5149-5153.
180. Yoshida K, Asaoka Y, Nishizuka Y. Platelet activation by simultaneous actions of diacylglycerol and unsaturated fatty acids. Proc Natl Acad Sci U S A 1992;89:6443-6446.
181. Knapp LT, Klann E. Superoxide-induced stimulation of protein kinase C via thiol modification and modulation of zinc content. . Biol Chem 2000;275: 24136-24145.
182. Kunisaki M, Bursell SE, Umeda F, et al. Normalization of diacylglycerolprotein kinase C activation by vitamin E in aorta of diabetic rats and cultured rat smooth muscle cells exposed to elevated glucose levels. Diabetes 1994;43: 1372-1377.
183. Koya D, Lee IK, Ishii H, et al. Prevention of glomerular dysfunction in diabetic rats by treatment with d-alpha-tocopherol. . Am Soc Nephrol 1997;8: 426-435.
184. Ricciarelli R, Tasinato A, Clement S, et al. alpha-Tocopherol specifically inactivates cellular protein kinase C alpha by changing its phosphorylation state. Biochem J 1998;334:243-249.
185. Tasinato A, Boscoboinik D, Bartoli GM, et al. d-alpha-Tocopherol inhibition of vascular smooth muscle cell proliferation occurs at physiological concentrations, correlates with protein kinase C inhibition, and is independent of its antioxidant properties. Proc Natl Acad Sci U S A 1995;92:12190-12194.
186. Tesfamariam B, Brown ML, Cohen RA. Elevated glucose impairs endotheliumdependent relaxation by activating protein kinase C. . Clin Invest 1991; 87:1643-1648.
187. Jack A, Cameron NE, Cotter MA. Treatment with the protein kinase CD inhibitor, LY333531, attenuates the development of impaired endotheliumdependent vasodilatation in the mesenteric vasculature of diabetic rats. Diabetes 1999(abst 558).
188. Beckman JA, Goldfine AB, Gordon MB, et al. Inhibition of protein kinase Cbeta prevents impaired endothelium-dependent vasodilation caused by hyperglycemia in humans. Circ Res 2002;90:107-111.
189. Zhang SL, Filep JG, Hohman TC, et al. Molecular mechanisms of glucose action on angiotensinogen gene expression in rat proximal tubular cells. Kidney Int 1999;55:454-464.
190. Hempel A, Maasch C, Heintze U, et al. High glucose concentrations increase endothelial cell permeability via activation of protein kinase C alpha. Circ Res 1997;81:363-371.
191. Williams B, Gallacher B, Patel H, et al. Glucose-induced protein kinase C activation regulates vascular permeability factor mRNA expression and peptide production by human vascular smooth muscle cells in vitro. Diabetes 1997;46: 1497-1503.
192. Park JY, Takahara N, Gabriele A, et al. Induction of endothelin-1 expression by glucose: an effect of protein kinase C activation. Diabetes 2000;49:1239-1248.
193. Xia P, Aiello LP, Ishii H, et al. Characterization of vascular endothelial growth factor's effect on the activation of protein kinase C, its isoforms, and endothelial cell growth. . Clin Invest 1996;98:2018-2026.
194. Suzuma K, Takahara N, Suzuma I, et al. Characterization of protein kinase C beta isoform's action on retinoblastoma protein phosphorylation, vascular endothelial growth factor-induced endothelial cell proliferation, and retinal neovascularization. Proc Natl Acad Sci U S A 2002;99:721-726.
195. Yokota T, Ma RC, Park JY, et al. Role of protein kinase C on the expression of platelet-derived growth factor and endothelin-1 in the retina of diabetic rats and cultured retinal capillary pericytes. Diabetes 2003;52:838-845.
196. Glogowski EA, Tsiani E, Zhou X, et al. High glucose alters the response of mesangial cell protein kinase C isoforms to endothelin-1. Kidney Int 1999;55: 486-499.
197. Laakso M, Edelman SV, Brechtel G, et al. Decreased effect of insulin to stimulate skeletal muscle blood flow in obese man. A novel mechanism for insulin resistance. . Clin Invest 1990;85:1844-1852.
198. Laakso M, Edelman SV, Brechtel G, et al. Impaired insulin-mediated skeletal muscle blood flow in patients with NIDDM. Diabetes 1992;41:1076-1083.
199. Yki-Jarvinen H, Utriainen T. Insulin-induced vasodilatation: physiology or pharmacology? Diabetologia 1998;41:369-379.
200. Bonadonna RC, Saccomani MP, Del Prato S, et al. Role of tissue-specific blood flow and tissue recruitment in insulin-mediated glucose uptake of human skeletal muscle. Circulation 1998;98:234-241.
201. Clark MG, Wallis MG, Barrett EJ, et al. Blood flow and muscle metabolism: a focus on insulin action. Am J Physiol Endocrinol Metab 2003;284:E241-E258.
202. Su EN, Yu DY, Alder VA, et al. Direct vasodilatory effect of insulin on isolated retinal arterioles. Invest Ophthalmol Vis Sci 1996;37:2634-2644.
203. Schmetterer L, Muller M, Fasching P, et al. Renal and ocular hemodynamic effects of insulin. Diabetes 1997;46:1868-1874.
204. Chen YL, Messina EJ. Dilation of isolated skeletal muscle arterioles by insulin is endothelium dependent and nitric oxide mediated. Am J Physiol 1996;270: H2120-H2124.
205. Steinberg HO, Brechtel G, Johnson A, et al. Insulin-mediated skeletal muscle vasodilation is nitric oxide dependent. A novel action of insulin to increase nitric oxide release. . Clin Invest 1994;94:1172-1179.
206. Duplain H, Burcelin R, Sartori C, et al. Insulin resistance, hyperlipidemia, and hypertension in mice lacking endothelial nitric oxide synthase. Circulation 2001;104:342-345.
207. Montagnani M, Chen H, Barr VA, et al. Insulin-stimulated activation of eNOS is independent of Ca2+ but requires phosphorylation by Akt at Ser(1179). . Biol Chem 2001;276:30392-30398.
208. Kuboki K, Jiang ZY, Takahara N, et al. Regulation of endothelial constitutive nitric oxide synthase gene expression in endothelial cells and in vivo: a specific vascular action of insulin. Circulation 2000;101:676-681.
209. Jiang ZY, Lin YW, Clemont A, et al. Characterization of selective resistance to insulin signaling in the vasculature of obese Zucker (fa/fa) rats. . Clin Invest 1999;104:447-457.
210. Govers R, Rabelink T. Cellular regulation of endothelial nitric oxide synthase. Am J Physiol 2001;280:F193-F206.
211. Folli F, Kahn CR, Hansen H, et al. Angiotensin II inhibits insulin signaling in aortic smooth muscle cells at multiple levels. Apotential role for serine phosphorylation in insulin/angiotensin II crosstalk. . Clin Invest 1997;100:2158-2169.
212. Vicent D, Ilany J, Kondo T, et al. The role of endothelial insulin signaling in the regulation of vascular tone and insulin resistance. . Clin Invest 2003;111: 1373-1380.
213. Poulaki V, Qin W, Joussen AM, et al. Acute intensive insulin therapy exacerbates diabetic blood-retinal barrier breakdown via hypoxia-inducible factor-1 alpha and VEGF. . Clin Invest 2002;109:805-815.
214. Kondo T, Vicent D, Suzuma K, et al. Knockout of insulin and IGF-1 receptors on vascular endothelial cells protects against retinal neovascularization. . Clin Invest 2003;111:1835-1842.
215. Morrisey K, Evans RA, Wakefield L, et al. Translational regulation of renal proximal tubular epithelial cell transforming growth factor-beta1 generation by insulin. Am J Pathol 2001;159:1905-1915.
216. Bennett BL, Satoh Y, Lewis AJ. JNK: a new therapeutic target for diabetes. Curr Opin Pharmacol 2003;3:420-425.
217. Natarajan R, Scott S, Bai W, et al. Angiotensin II signaling in vascular smooth muscle cells under high glucose conditions. Hypertension 1999;33:378-384.
218. Igarashi M, Wakasaki H, Takahara N, et al. Glucose or diabetes activates p38 mitogen-activated protein kinase via different pathways. . Clin Invest 1999; 103:185-195.
219. Haneda M, Araki S, Togawa M, et al. Mitogen-activated protein kinase cascade is activated in glomeruli of diabetic rats and glomerular mesangial cells cultured under high glucose conditions. Diabetes 1997;46:847-853.
220. Wolf G. Cell cycle regulation in diabetic nephropathy. Kidney Int Suppl 2000; 77:S59-S66.
221. Al-Douahji M, Brugarolas J, Brown PA, et al. The cyclin kinase inhibitor p21WAF1/CIP1 is required for glomerular hypertrophy in experimental diabetic nephropathy. Kidney Int 1999;56:1691-1699.
222. Awazu M, Omori S, Ishikura K, et al. The lack of cyclin kinase inhibitor p27(Kip1) ameliorates progression of diabetic nephropathy. . Am Soc Nephrol 2003;14:699-708.
223. Wolf G, Shankland SJ. P27Kip1: the "rosebud" of diabetic nephropathy? . Am Soc Nephrol 2003;14:819-822.
224. Feliers D, Frank MA, Riley DJ. Activation of cyclin D1-Cdk4 and Cdk4-directed phosphorylation of RB protein in diabetic mesangial hypertrophy. Diabetes 2002;51:3290-3299.
225. Sanchez-Elsner T, Botella LM, Velasco B, et al. Synergistic cooperation between hypoxia and transforming growth factor-beta pathways on human vascular endothelial growth factor gene expression. . Biol Chem 2001;276: 38527-38535.
226. Autiero M, Waltenberger J, Communi D, et al. Role of PlGF in the intra-and intermolecular cross talk between the VEGF receptors Flt1 and Flk1. Nat Med 2003;9:936-943.
227. Smith LE, Shen W, Perruzzi C, et al. Regulation of vascular endothelial growth factor-dependent retinal neovascularization by insulin-like growth factor-1 receptor. Nat Med 1999;5:1390-1395.
228. Cao R, Brakenhielm E, Pawliuk R, et al. Angiogenic synergism, vascular stability and improvement of hind-limb ischemia by a combination of PDGF-BB and FGF-2. Nat Med 2003;9:604-613.
229. Boulton M, Gregor Z, McLeod D, et al. Intravitreal growth factors in proliferative diabetic retinopathy: correlation with neovascular activity and glycaemic management. Br J Ophthalmol 1997;81:228-233.
230. Sivalingam A, Kenney J, Brown GC, et al. Basic fibroblast growth factor levels in the vitreous of patients with proliferative diabetic retinopathy. Arch Ophthalmol 1990;108:869-872.
231. Seghezzi G, Patel S, Ren CJ, et al. Fibroblast growth factor-2 (FGF-2) induces vascular endothelial growth factor (VEGF) expression in the endothelial cells of forming capillaries: an autocrine mechanism contributing to angiogenesis. . Cell Biol 1998;141:1659-1673.
232. Ozaki H, Okamoto N, Ortega S, et al. Basic fibroblast growth factor is neither necessary nor sufficient for the development of retinal neovascularization. Am J Pathol 1998;153:757-765.
233. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003;9:669-676.
234. Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. . Engl J Med 1994;331:1480-1487.
235. Boulton M, Foreman D, Williams G, et al. VEGF localisation in diabetic retinopathy. Br J Ophthalmol 1998;82:561-568.
236. Hammes HP, Lin J, Bretzel RG, et al. Upregulation of the vascular endothelial growth factor/vascular endothelial growth factor receptor system in experimental background diabetic retinopathy of the rat. Diabetes 1998;47: 401-406.
237. Aiello LP, Pierce EA, Foley ED, et al. Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc Natl Acad Sci U S A 1995;92: 10457-10461.
238. Cooper ME, Vranes D, Youssef S, et al. Increased renal expression of vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in experimental diabetes. Diabetes 1999;48:2229-2239.
239. Bortoloso E, Del Prete D, Gambaro G, et al. Vascular endothelial growth factor (VEGF) and VEGF receptors in diabetic nephropathy: expression studies in biopsies of type 2 diabetic patients. Ren Fail 2001;23:483-493.
240. de Vriese AS, Tilton RG, Elger M, et al. Antibodies against vascular endothelial growth factor improve early renal dysfunction in experimental diabetes. . Am Soc Nephrol 2001;12:993-1000.
241. Flyvbjerg A, Dagnaes-Hansen F, De Vriese AS, et al. Amelioration of longterm renal changes in obese type 2 diabetic mice by a neutralizing vascular endothelial growth factor antibody. Diabetes 2002;51:3090-3094.
242. Duh E, Aiello LP. Vascular endothelial growth factor and diabetes: the agonist versus antagonist paradox. Diabetes 1999;48:1899-1906.
243. Giordano FJ, Gerber HP, Williams SP, et al. A cardiac myocyte vascular endothelial growth factor paracrine pathway is required to maintain cardiac function. Proc Natl Acad Sci U S A 2001;98:5780-5785.
244. Losordo DW, Vale PR, Hendel RC, et al. Phase 1/2 placebo-controlled, doubleblind, dose-escalating trial of myocardial vascular endothelial growth factor 2 gene transfer by catheter delivery in patients with chronic myocardial ischemia. Circulation 2002;105:2012-2018.
245. Henry TD, Annex BH, McKendall GR, et al. The VIVA trial: vascular endothelial growth factor in ischemia for vascular angiogenesis. Circulation 2003;107:1359-1365.
246. Freyberger H, Brocker M, Yakut H, et al. Increased levels of platelet-derived growth factor in vitreous fluid of patients with proliferative diabetic retinopathy. Exp Clin Endocrinol Diabetes 2000;108:106-109.
247. Koyama N, Watanabe S, Tezuka M, et al. Migratory and proliferative effect of platelet-derived growth factor in rabbit retinal endothelial cells: evidence of an autocrine pathway of platelet-derived growth factor. . Cell Physiol 1994; 158:1-6.
248. Inaba T, Ishibashi S, Gotoda T, et al. Enhanced expression of platelet-derived growth factor-beta receptor by high glucose. Involvement of platelet-derived growth factor in diabetic angiopathy. Diabetes 1996;45:507-512.
249. Fraser D, Wakefield L, Phillips A. Independent regulation of transforming growth factor-beta1 transcription and translation by glucose and plateletderived growth factor. Am J Pathol 2002;161:1039-1049.
250. Hammes HP, Lin J, Renner O, et al. Pericytes and the pathogenesis of diabetic retinopathy. Diabetes 2002;51:3107-3112.
251. Enge M, Bjarnegard M, Gerhardt H, et al. Endothelium-specific plateletderived growth factor-B ablation mimics diabetic retinopathy. EMBO J 2002; 21:4307-4316.
252. Sharma K, Ziyadeh FN, Alzahabi B, et al. Increased renal production of transforming growth factor-beta1 in patients with type II diabetes. Diabetes 1997; 46:854-859.
253. Iwano M, Kubo A, Nishino T, et al. Quantification of glomerular TGF-beta 1 mRNA in patients with diabetes mellitus. Kidney Int 1996;49:1120-1126.
254. Hong SW, Isono M, Chen S, et al. Increased glomerular and tubular expression of transforming growth factor-beta1, its type II receptor, and activation of the Smad signaling pathway in the db/db mouse. Am J Pathol 2001;158: 1653-1663.
255. Han DC, Hoffman BB, Hong SW, et al. Therapy with antisense TGF-beta1 oligodeoxynucleotides reduces kidney weight and matrix mRNAs in diabetic mice. Am J Physiol Renal Physiol 2000;278:F628-F634.
256. Yang YL, Guh JY, Yang ML, et al. Interaction between high glucose and TGFbeta in cell cycle protein regulations in MDCK cells. . Am Soc Nephrol 1998;9: 182-193.
257. Poncelet AC, Schnaper HW. Sp1 and Smad proteins cooperate to mediate transforming growth factor-beta 1-induced alpha 2(I) collagen expression in human glomerular mesangial cells. . Biol Chem 2001;276:6983-6992.
258. Ziyadeh FN, Sharma K, Ericksen M, et al. Stimulation of collagen gene expression and protein synthesis in murine mesangial cells by high glucose is mediated by autocrine activation of transforming growth factor-beta. . Clin Invest 1994;93:536-542.
259. Han DC, Isono M, Hoffman BB, et al. High glucose stimulates proliferation and collagen type I synthesis in renal cortical fibroblasts: mediation by autocrine activation of TGF-beta. . Am Soc Nephrol 1999;10:1891-1899.
260. Chen S, Cohen MP, Lautenslager GT, et al. Glycated albumin stimulates TGFbeta 1 production and protein kinase C activity in glomerular endothelial cells. Kidney Int 2001;59:673-681.
261. Wolf G, Hamann A, Han DC, et al. Leptin stimulates proliferation and TGFbeta expression in renal glomerular endothelial cells: potential role in glomerulosclerosis. Kidney Int 1999;56:860-872.
262. Han DC, Isono M, Chen S, et al. Leptin stimulates type I collagen production in db/db mesangial cells: glucose uptake and TGF-beta type II receptor expression. Kidney Int 2001;59:1315-1323.
263. Gupta S, Clarkson MR, Duggan J, et al. Connective tissue growth factor: potential role in glomerulosclerosis and tubulointerstitial fibrosis. Kidney Int 2000;58:1389-1399.
264. Wahab NA, Yevdokimova N, Weston BS, et al. Role of connective tissue growth factor in the pathogenesis of diabetic nephropathy. Biochem J 2001; 359:77-87.
265. Riser BL, Denichilo M, Cortes P, et al. Regulation of connective tissue growth factor activity in cultured rat mesangial cells and its expression in experimental diabetic glomerulosclerosis. . Am Soc Nephrol 2000;11:25-38.
266. Murphy M, Godson C, Cannon S, et al. Suppression subtractive hybridization identifies high glucose levels as a stimulus for expression of connective tissue growth factor and other genes in human mesangial cells. . Biol Chem 1999;274:5830-5834.
267. Chen Y, Blom IE, Sa S, et al. CTGF expression in mesangial cells: involvement of SMADs, MAP kinase, and PKC. Kidney Int 2002;62:1149-1159.
268. Way KJ, Isshiki K, Suzuma K, et al. Expression of connective tissue growth factor is increased in injured myocardium associated with protein kinase C beta2 activation and diabetes. Diabetes 2002;51:2709-2718.
269. Bereket A, Lang CH, Wilson TA. Alterations in the growth hormone-insulinlike growth factor axis in insulin dependent diabetes mellitus. Horm Metab Res 1999;31:172-181.
270. Doi T, Striker LJ, Quaife C, et al. Progressive glomerulosclerosis develops in transgenic mice chronically expressing growth hormone and growth hormone releasing factor but not in those expressing insulinlike growth factor-1. Am J Pathol 1988;131:398-403.
271. Chen NY, Chen WY, Bellush L, et al. Effects of streptozotocin treatment in growth hormone (GH) and GH antagonist transgenic mice. Endocrinology 1995;136:660-667.
272. Bellush LL, Doublier S, Holland AN, et al. Protection against diabetesinduced nephropathy in growth hormone receptor/binding protein genedisrupted mice. Endocrinology 2000;141:163-168.
273. Smith LE, Kopchick JJ, Chen W, et al. Essential role of growth hormone in ischemia-induced retinal neovascularization. Science 1997;276:1706-1709.
274. Gilbert RE, Krum H, Wilkinson-Berka J, et al. The renin-angiotensin system and the long-term complications of diabetes: pathophysiological and therapeutic considerations. Diabet Med 2003;20:607-621.
275. Malik RA, Williamson S, Abbott C, et al. Effect of angiotensin-convertingenzyme (ACE) inhibitor trandolapril on human diabetic neuropathy: randomised double-blind controlled trial. Lancet 1998;352:1978-1981.
276. Mehler PS, Jeffers BW, Estacio R, et al. Associations of hypertension and complications in non-insulin-dependent diabetes mellitus. Am J Hypertens 1997; 10:152-161.
277. Anderson S, Rennke HG, Garcia DL, et al. Short and long term effects of antihypertensive therapy in the diabetic rat. Kidney Int 1989;36:526-536.
278. Allen TJ, Cao Z, Youssef S, et al. Role of angiotensin II and bradykinin in experimental diabetic nephropathy. Functional and structural studies. Diabetes 1997;46:1612-1618.
279. Zatz R, Dunn BR, Meyer TW, et al. Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension. . Clin Invest 1986;77:1925-1930.
280. Navar LG, Lewis L, Hymel A, et al. Tubular fluid concentrations and kidney contents of angiotensins I and II in anesthetized rats. . Am Soc Nephrol 1994; 5:1153-1158.
281. Kagami S, Border WA, Miller DE, et al. Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-beta expression in rat glomerular mesangial cells. . Clin Invest 1994;93: 2431-2437.
282. Kawano H, Do YS, Kawano Y, et al. Angiotensin II has multiple profibrotic effects in human cardiac fibroblasts. Circulation 2000;101:1130-1137.
283. Chen MM, Lam A, Abraham JA, et al. CTGF expression is induced by TGFbeta in cardiac fibroblasts and cardiac myocytes: a potential role in heart fibrosis. . Mol Cell Cardiol 2000;32:1805-1819.
284. Chen HC, Bouchie JL, Perez AS, et al. Role of the angiotensin AT(1) receptor in rat aortic and cardiac PAI-1 gene expression. Arterioscler Thromb Vasc Biol 2000;20:2297-2302.
285. Price DA, Porter LE, Gordon M, et al. The paradox of the low-renin state in diabetic nephropathy. . Am Soc Nephrol 1999;10:2382-2391.
286. Schunkert H, Ingelfinger JR, Jacob H, et al. Reciprocal feedback regulation of kidney angiotensinogen and renin mRNA expressions by angiotensin II. Am J Physiol 1992;263:E863-E869.
287. Osanai T, Fujita N, Fujiwara N, et al. Cross talk of shear-induced production of prostacyclin and nitric oxide in endothelial cells. Am J Physiol Heart Circ Physiol 2000;278:H233-H238.
288. Huang A, Sun D, Smith CJ, et al. In eNOS knockout mice skeletal muscle arteriolar dilation to acetylcholine is mediated by EDHF. Am J Physiol Heart Circ Physiol 2000;278:H762-H768.
289. Koltai MZ, Hadhazy P, Posa I, et al. Characteristics of coronary endothelial dysfunction in experimental diabetes. Cardiovasc Res 1997;34:157-163.
290. Zanetti M, Sato J, Katusic ZS, et al. Gene transfer of endothelial nitric oxide synthase alters endothelium-dependent relaxations in aortas from diabetic rabbits. Diabetologia 2000;43:340-347.
291. Ding Y, Vaziri ND, Coulson R, et al. Effects of simulated hyperglycemia, insulin, and glucagon on endothelial nitric oxide synthase expression. Am J Physiol Endocrinol Metab 2000;279:E11-E17.
292. Cosentino F, Hishikawa K, Katusic ZS, et al. High glucose increases nitric oxide synthase expression and superoxide anion generation in human aortic endothelial cells. Circulation 1997;96:25-28.
293. Hink U, Li H, Mollnau H, et al. Effects of diabetes mellitus on nitric oxide synthase (NOS III) expression, NOS III mediated superoxide production and vascular nitric oxide bioavailability. Circulation 1999;100:I-235(abst).
294. Lund DD, Faraci FM, Miller FJ Jr, et al. Gene transfer of endothelial nitric oxide synthase improves relaxation of carotid arteries from diabetic rabbits. Circulation 2000;101:1027-1033.
295. Zhao X, Lu X, Feng Q. Deficiency in endothelial nitric oxide synthase impairs myocardial angiogenesis. Am J Physiol Heart Circ Physiol 2002;283:H2371-H2378.
296. Studer RK, DeRubertis FR, Craven PA. Nitric oxide suppresses increases in mesangial cell protein kinase C, transforming growth factor beta, and fibronectin synthesis induced by thromboxane. . Am Soc Nephrol 1996;7:999-1005.
297. Craven PA, Studer RK, Felder J, et al. Nitric oxide inhibition of transforming growth factor-beta and collagen synthesis in mesangial cells. Diabetes 1997; 46:671-681.
298. Venugopal SK, Devaraj S, Jialal I. C-reactive protein decreases prostacyclin release from human aortic endothelial cells. Circulation 2003;108:1676-1678.
299. Cosentino F, Eto M, De Paolis P, et al. High glucose causes upregulation of cyclooxygenase-2 and alters prostanoid profile in human endothelial cells: role of protein kinase C and reactive oxygen species. Circulation 2003;107: 1017-1023.
300. Tesfamariam B, Brown ML, Deykin D, et al. Elevated glucose promotes generation of endothelium-derived vasoconstrictor prostanoids in rabbit aorta. . Clin Invest 1990;85:929-932.
301. Hopfner RL, Gopalakrishnan V. Endothelin: emerging role in diabetic vascular complications. Diabetologia 1999;42:1383-1394.
302. Mather KJ, Mirzamohammadi B, Lteif A, et al. Endothelin contributes to basal vascular tone and endothelial dysfunction in human obesity and type 2 diabetes. Diabetes 2002;51:3517-3523.
303. Lee ME, Dhadly MS, Temizer DH, et al. Regulation of endothelin-1 gene expression by Fos and Jun. . Biol Chem 1991;266:19034-19039.
304. Takagi C, Bursell SE, Lin YW, et al. Regulation of retinal hemodynamics in diabetic rats by increased expression and action of endothelin-1. Invest Ophthalmol Vis Sci 1996;37:2504-2518.
305. Merkus D, Duncker DJ, Chilian WM. Metabolic regulation of coronary vascular tone: role of endothelin-1. Am J Physiol Heart Circ Physiol 2002;283: H1915-H1921.
306. Oliver FJ, de la Rubia G, Feener EP, et al. Stimulation of endothelin-1 gene expression by insulin in endothelial cells. . Biol Chem 1991;266:23251-23256.
307. Cardillo C, Nambi SS, Kilcoyne CM, et al. Insulin stimulates both endothelin and nitric oxide activity in the human forearm. Circulation 1999;100: 820-825.
308. Hocher B, Thone-Reineke C, Rohmeiss P, et al. Endothelin-1 transgenic mice develop glomerulosclerosis, interstitial fibrosis, and renal cysts but not hypertension. . Clin Invest 1997;99:1380-1389.
309. Quaschning T, Kocak S, Bauer C, et al. Increase in nitric oxide bioavailability improves endothelial function in endothelin-1 transgenic mice. Nephrol Dial Transplant 2003;18:479-483.
310. Schwarz A, Godes M, Thone-Reineke C, et al. Tissue-dependent expression of matrix proteins in human endothelin-1 transgenic mice. Clin Sci (Lond) 2002;103[Suppl]48:39S-43S.
311. Evans T, Deng DX, Chen S, et al. Endothelin receptor blockade prevents augmented extracellular matrix component mRNA expression and capillary basement membrane thickening in the retina of diabetic and galactose-fed rats. Diabetes 2000;49:662-666.
312. Rodriguez-Pascual F, Redondo-Horcajo M, Lamas S. Functional cooperation between Smad proteins and activator protein-1 regulates transforming growth factor-beta-mediated induction of endothelin-1 expression. Circ Res 2003;92: 1288-1295.
313. Risso A, Mercuri F, Quagliaro L, et al. Intermittent high glucose enhances apoptosis in human umbilical vein endothelial cells in culture. Am J Physiol Endocrinol Metab 2001;281:E924-E930.